Iovance's Amtagvi achieved a 44% confirmed objective response rate and 73% disease control in an advanced melanoma study. Goldman Sachs raised its price target to $2, maintaining a Sell rating.
CAR T-cell therapy is delivering high remission rates for multiple myeloma patients, with improved handoff communication reducing infection risks. FDA-approved BCMA-targeting products show response rates from 72% to 98% in heavily pretreated patients.
Researchers developed BIOPREVENT, an AI-based tool that predicts chronic graft-versus-host disease and transplant-related mortality in stem cell and bone marrow transplant patients by analyzing blood biomarkers and clinical data collected 90-100 days post-transplant.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07563010 |
Menin-Inhibitor Targeted Maintenance in AML |
NOT_YET_RECRUITING | PHASE2 |
| NCT06859424 |
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation |
RECRUITING | PHASE2 |
| NCT06271512 |
A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel |
RECRUITING | |
| NCT06224413 |
A Study of Participants With Cerebral Adrenoleukodystrophy (CALD) Treated With Elivaldogene Autotemcel |
RECRUITING | |
| NCT06001385 |
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT05784415 |
Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell |
COMPLETED | |
| NCT05600426 |
A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202) |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT05224661 |
Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events |
TERMINATED | |
| NCT04920474 |
Protocol for a Research Sample Repository for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries |
RECRUITING | |
| NCT04904588 |
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide |
ACTIVE_NOT_RECRUITING | PHASE2 |
